Werkgroep Cardiologische centra Nederland

dal-GenE (Follow-up)

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS). The Dal-GenE trial
Medicine
dalcetrapib
Population
ASCVD
Phase
III
Starting year
2015
More information
ClinicalTrials.gov

Director of Study

drs. H.P. Swart (Cardioloog)
Sneek, D&A Research and Genetics